Agendia develops genomic tests to help support physicians faced with complex treatment decisions for women with breast cancer. MammaPrint®, the 70-gene breast cancer recurrence assay, is the only FDA-cleared breast cancer recurrence assay, backed by peer-reviewed, prospective outcome data, included in national and international guidelines. BluePrint®, the 80-gene molecular subtyping assay looks beyond the cell surface to identify Luminal-type, Basal-type and HER2-type breast cancer. Learn more at: https://agendia.com/
Bristol Myers Squibb is a leading global biopharma company focused on discovering, developing and delivering innovative medicines for patients with serious diseases in areas including oncology, hematology, immunology, cardiovascular, fibrosis and neuroscience. Our employees work every day to transform patients’ lives through science.
Transforming Cancer Treatments Through World Leading Hyperthermic Technologies
COMBAT Medical’s patented hyperthermic technologies are helping to transform cancer treatments globally. Used in hospitals in over 40 countries worldwide to treat bladder and peritoneal cancers.
Combat is committed to investing in research and development, clinical trials and evidence-based studies to prove the efficacy of its technology and create a solid foundation for use. Over 1000 patients are currently in clinical trials and in excess of 2000 treatments are given to patients each month.
Combat works closely with healthcare professionals worldwide and partners with a global network of distributors to ensure that its devices are available to bladder and peritoneal cancer patients in as many countries as possible.
IntraOp® is the leading innovator of electron therapy devices for treating cancer. IntraOp’s compact and mobile linear accelerators enable oncologists to deliver effective, precise, and affordable radiation therapy at the point of care.
The Mobetron® is the most comprehensive electron therapy linear accelerator system with applications in intraoperative radiotherapy (IORT) and non-invasive treatment of skin cancer. Now Mobetron is the first to offer ultra-high dose rate electron therapy for preclinical and investigational studies of FLASH radiotherapy, providing researchers an approach not possible before: Precision treatment in microseconds.
Our technology unlocks new treatment options for patients and increases the accessibility of effective treatment. Leading oncologists, hospitals, and research centers all over the world utilize IntraOp’s products to improve patient care.
ENCARE - Encare develops and promotes interactive digital tools and services to support healthcare professionals to implement and sustain best clinical practice for improved quality of care.
At Endomag, we believe everyone deserves a better standard of cancer care. Many of the world’s leading physicians and hospitals use our magnetic technologies to help women with breast cancer avoid surgery when it isn’t needed, and experience better outcomes when it is.
The Magseed® marker is a tiny, non-radioactive seed, ideal for accurately marking tumours and lymph nodes. Meanwhile, the Magtrace® lymphatic tracer is the world’s first, long-lasting, non-radioactive dual tracer for lymphatic mapping.
To date, Magseed® and Magtrace® have helped 160,000+ women around the world access more precise and less invasive breast care.
Find out more at www.endomag.com
At Johnson & Johnson Medical Devices Companies (JJMDC), we are using our breadth, scale and experience to reimagine the way healthcare is delivered and help people live longer, healthier lives.
In a radically changing environment, we are making connections across science and technology to combine our own expertise in surgery and interventional solutions with the big ideas of others to design and deliver physician and patient-centric products and solutions.
As pioneers in medical devices, we continually focus on elevating the standard of care – working to expand patient access, improve outcomes, reduce health system costs and drive value. We create smart, people-centered healthcare to help the patients we serve recover faster and live longer and more vibrantly.
We are in this for life.
GEM is an Italian manufacturer and distributor of medical devices. It was founded in 1994 with a business culture primarily based on research, development, production and marketing of innovative medical devices. In 1995 GEM commercializes the Glubran glue, to be used in surgical procedures, and, soon after, the Glubran 2, with a new formula that allows its use even in endovascular procedures.
In these years GEM has designed and manufactured many application devices for the glue in order to facilitate and enhance its use.
At present Glubran 2, Glubran Tiss 2 (the skin adhesive) and their application devices are sold in over 40 countries worldwide.
Our work is based on the continuous research and its aim is to develop innovative surgical medical devices, in order to anticipate the demands of an increasingly sophisticated market.
Meccellis Biotech is born from the meeting of a Biological Engineering and two engineers specialized in surgery Affairs. These three experts have combined their experience and know-how to make of Meccellis Biotech a company expert in Tissue and Cell Engineering with a diversified offer for multiple surgical specialties.
After 10 years of marketing, Meccellis Biotech is now present in 25 countries.
The passion and professionalism of its teams have made of Meccellis Biotech, a reference company in biomaterials.
Medica Group is operating since 1985 in the biomedical district of Mirandola (Italy).
Development of innovative products for blood purification, urology, organ transplant and Chemohyperthermia has always been company's core business. R&D focus has been integrated over the years with a broad offer of sterile single use products manufactured in two facilities, one in Italy and one in Tunisia, with a highly automated production systems. l We offer to Surgical Oncologists a new system, called FLEXIPER for Chemohyperthermia with State of Art features.
Located in the internationally well-known Mirandola bio-medical distric (Italy), RanD is a knowledge-based company, establisehd in 1999 exploiting more than 30 years‘ experience. RanD has 20 years‘ experience in the field of Surgical Oncology. It is the 1st market leader present in over 50 countries worldwide and with more than 35.000 patients treated with HIPEC.
RanD is specialized in the development of innovative devices based on extracorporeal circulation technologies, marked, at the same time, by extremely simplified operative managemernt.
During the years RanD has established a close collaboration with internationally renowned physicians, providing their essential contribution to the development of systems meeting real users‘ needs. To this purpose RanD is in active cooperation with the committees of congresses and international scientific societies; it also performs a constant educational activity addressed to physicians and technicians in the field.
SamanTree Medical SA proposes a breakthrough innovation with the will to improve cancer treatment: the Histolog® Scanner. This new imaging modality finds its application along the patient journey, from biopsy taking to surgical diagnostics.
The company was founded in December 2014 and is a spin-off of the Ecole Polytechnique Fédérale de Lausanne (EPFL). Since 2016, the Histolog Scanner is a CE mark product for high resolution imaging of the surface of fresh tissue. It is based on a novel ultra-fast confocal microscopy technology invented in EPFL in 2010.
With its roots in the Netherlands Cancer Institute, Sirius Medical was born to make things better. The Sirius Pintuition system was developed by and for surgeons addressing a clear clinical need with a solution that simply makes sense. The Sirius Pintuition system is CE marked and received FDA clearance and is currently commercially available in Western Europe. Our mission is to improve care for cancer patients by delivering unsurpassed, yet affordable solutions that enable precise and efficient surgical removal of tumors.
S.I.T. – Sordina IORT Technologies is one of the few worldwide players capable of designing, manufacturing, distributing and performing after sales service of miniaturized mobile electron linear accelerators for Intra Operative electron Radiation Therapy (IOeRT) and for FLASH Radiation Therapy systems. People at S.I.T. are moved by a strong passion for discovering, developing and producing new technologies to fight against cancer.
Our system’s performances are possible thanks to innovative and tailored technical solutions particularly studied to offer top quality combined with a personalized service to our global users.
Stryker is one of the world's leading medical technology companies and, together with its customers, is driven to make healthcare better. The company offers innovative products and services in Orthopaedics, Medical and Surgical, and Neurotechnology and Spine that help improve patient and hospital outcomes.
Sysmex supports healthcare professionals around the world in lighting the way with diagnostics by providing a broad range of medical diagnostics products and solutions. In the fields of haematology, urinalysis, haemostasis, life science, flow cytometry, essential healthcare and now immunochemistry, we combine highly dependable, multi-functional and easy-to-operate instruments, a variety of reagents and software, plus reliable service and support.
Sysmex Europe GmbH, located near Hamburg, Germany, is a subsidiary of the Sysmex Corporation from Kobe, Japan. From our Hamburg offices, we serve our affiliates, distributors and customers throughout Europe, the Middle East, and Africa (EMEA). For more information, visit www.sysmex-europe.com.
Thompson Surgical Instruments, Inc.
Thompson Surgical celebrates over 55 years as a leader in exposure and the original manufacturer of the table-mounted retractor. We understand the value of exposure in surgery and are dedicated to providing innovative, high quality systems that deliver safe, versatile, and low-profile retraction. From pediatric to obesity, simple to complex exposures, we offer unlimited customization and safe, independent, retraction. The Thompson Retractor allows surgeons in multiple specialties to achieve Uncompromised Exposure.
Concerned about the risk of re-excision with breast conserving surgery?
As a healthcare professional, you want to avoid resurgery and improve your patient’s chances of recovery at all costs.
At XEOS, we develop smarter specimen imaging solutions that help you achieve that goal.
With the XEOS AURA 10, the first-ever PET-CT specimen imager for the OR, we have made it possible to obtain reference image quality in your OR within minutes after excision.
Visit XEOS to discover the benefits of the AURA 10 PET-CT specimen imager and how we are taking a huge step forward in surgical oncology.
Founded in Ghent, Belgium in 2019, Xeos has grown to become a team of bright and passionate minds. We host a wealth of competence in the medical device industry, medical image reconstruction and processing, and fundamental scientific research. We hold a strong track record of inhouse PET & CT design. We are adepts of molecular imaging.